期刊文献+

营养物质刺激肠道L细胞分泌GLP-1的机制 被引量:4

The mechanisms of nutrient-stimulated GLP-1 secretion from intestinal L-cells
原文传递
导出
摘要 在营养物质的刺激作用下,肠上皮的L细胞分泌胰高血糖素样肽-1(GLP-1),后者具有控制餐后血糖和食欲的重要作用。这些营养物质包括糖类物质、蛋白质、脂类物质,其中糖类物质刺激L细胞分泌GLP-1的机制包括ATP敏感的K通道(KATP通道)、钠-葡萄糖协同转运体(SGLT)1、味觉受体通路;蛋白质刺激L细胞分泌GLP-1的机制可能为电压门控的Ca^2+通道、Na+-K+-2Cl-同向转运体、促离子型1-氨基丁酸(GABA)受体、Na+耦联转运体所致的细胞膜去极化;脂类物质刺激L细胞分泌GLP-1的机制可能与脂肪酸敏感的G蛋白耦联受体(GRPs)有关。 In response to the stimulation of nutrients, glucagon-like peptide-1 (GLP-1) is secreted from the intestinal epithelial L-cells, which is important to postprandial plasma glucagon modulation and appetite control. The nutrients include carbohydrates, proteins and lipids. Carbohydrates stimulate GLP-1 release from L-cells by ATP-sensitive K + channel( KATP channel) ,sodium-glucose cotransporter(SGLT) 1 and taste receptor pathways. Proteins stimulate GLP-1 release from L-cells by plasma membrane depolarization which is initiated by voltage gated Ca2+ -channels, Na+ -K+ -2Cl- cotransporters, ionotropic GABA receptor and Na+ -coupled transporters, while lipids stimulate GLP-1 release from L-cells by fatty acids-sensitive G-protein coupled receptors.
出处 《国际内分泌代谢杂志》 2011年第5期324-326,共3页 International Journal of Endocrinology and Metabolism
基金 国家自然科学基金资助项目(81070621/H0704,30971404/C140406)
关键词 营养物质 L细胞 胰高血糖素样肽-1 Nutrients L cells Glucagon-like peptide-1
  • 相关文献

参考文献27

  • 1Hoist JJ. The physiology of glucagon-like peptide 1. Physiol Rev, 2007,87 : 1409 - 1439.
  • 2Stephens JW. The incretin system in the management of type 2 diabetes mellitus. Clin Med ,2010,10:491-495.
  • 3Reimann F, Habib AM, Tolhurst G, et al. Glucose sensing in L cells: a primary cell study. Cell Metab,2008 ,8 :532-539.
  • 4Cani PD,Holst JJ,Drucker DJ,et al. GLUT2 and the incretin re- ceptors are involved in glucose-induced incretin secretion. Mol Cell Endocrinol,2007,276 : 18-23.
  • 5Nielsen LB, Ploug KB, Swift P, et al. Co-localisation of the Kit6.2/SUR1 channel complex with glucagon-like peptide-1 and glucose-dependent insulinotrophic polypeptide expression in hu- man ileal cells and implications for glycaemic control in new onset type 1 diabetes. Eur J Endocrinol,2007,156:663-671.
  • 6E1-Ouaghlidi A,Rehring E, Hoist JJ, et al. The dipeptidyl pepti- dase 4 inhibitor vildagliptin does not accentuate glibenclamide-in- duced hypoglycemia but reduces glucose-induced glucagon-like pep|ide L and gastric inhibitory polypeptide secretion. J Clin Endocrinol Metab ,2007,92:4165-4171.
  • 7Murphy R, Tura A, Clark PM, et al. Glucokinase, the pancreatic glucose sensor,is not the gut glucose sensor. Diabetologia,2009, 52:154-159.
  • 8Pearson ER,Flechtner I, Njolstad PR, et al. Switching from insu- lin to oral sulfonylureas in patients with diabetes due Io Kit6.2 mutations. N Engl J Med,2006,355:467-477.
  • 9Moriya R, Shirakura T, Ito J, et al. Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice. Am J Physiol Endocrinol Metab, 2009,297: EI358-E1365.
  • 10Wright EM, Hirayama BA, Loo DF. Active sugar transport in heath and disease. J Intern Med,2007,261:32-43.

同被引文献127

  • 1Liu WJ, Xie SH, Liu YN, et al. Dipeptidyl peptidase 1V in-hibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther,2012,340:248-255.
  • 2Lone AM, Nohe WM, Tinoco AD, et al. Peptidomics of the prolyl peptidases. AAPS J,2010,12:483-491.
  • 3Panchapakesan U, Mather A, Pollock C. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease. Clin Sci (Lond),2013,124:17-26.
  • 4Namba M, Katsuno T, Kusunoki Y, et al. New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy. Clin Exp Nephrol,2013,17:10-15.
  • 5Mega C, de Lemos ET, Vala H, et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res, 2011,2011:162092.
  • 6Thomson SC, Kashkouli A, Singh P. Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat. Am J Physiol Renal Physiol,2013,304: F137-F144.
  • 7Kodera R, Shikata K, Kataoka HU, et al. Glucagon-like pep- tide-1 receptor agonist ameliorates renal injury through its an- ti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia,2011,54:965-978.
  • 8Ishibashi Y, Nishino Y, Matsui T, et al. Glucagon-like peptide- 1 sup- presses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism,2011,60:1271-1277.
  • 9Hirata K, Kume S, Araki S, et al. Exendin-4 has an anti-hy- pertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun,2009,380:44-49.
  • 10Liu Q, Adams L, Broyde A, et al. The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunc- tion in Dahl salt-sensitive rats. Cardiovasc Diabetol,2010,9:32.

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部